Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Whartenby

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cancer Gene Therapy|May 7, 2011
Induction of the glucocorticoid-induced leucine zipper gene limits the efficacy of dendritic cell vaccinesL Lebson, T Wang, Q Jiang, et al.
Drugs|December 1, 1995
Gene therapy. Clinical potential and relationship to drug treatmentK A Whartenby, A J Marrogi, S M Freeman
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 1, 1995
The biology of cancer gene therapyK A Whartenby, C N Abboud, A J Marrogi, et al.
Acta Virologica|April 1, 1993
Oncogene elements within an endogenous retrovirusK A Whartenby, R A Insel, S M Freeman, et al.
Seminars in Oncology|February 1, 1996
In situ use of suicide genes for cancer therapyS M Freeman, K A Whartenby, J L Freeman, et al.
Neurology|January 24, 2002
An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MSP A Calabresi, J L Wilterdink, J M Rogg, et al.
Pharmacology & Therapeutics|April 1, 1995
Gene-modified cells for the treatment of cancerK A Whartenby, G N Abraham, P A Calabresi, et al.
Journal of Neuroimmunology|June 28, 2008
Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitisM V Jones, T T Nguyen, C A Deboy, et al.
Cancer Research|November 1, 1993
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modifiedS M Freeman, C N Abboud, K A Whartenby, et al.
Leukemia|February 3, 2007
Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative diseaseB R Baldwin, L Li, K-F Tse, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancer Gene Therapy|May 7, 2011
Induction of the glucocorticoid-induced leucine zipper gene limits the efficacy of dendritic cell vaccinesL Lebson, T Wang, Q Jiang, et al.
Drugs|December 1, 1995
Gene therapy. Clinical potential and relationship to drug treatmentK A Whartenby, A J Marrogi, S M Freeman
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 1, 1995
The biology of cancer gene therapyK A Whartenby, C N Abboud, A J Marrogi, et al.
Acta Virologica|April 1, 1993
Oncogene elements within an endogenous retrovirusK A Whartenby, R A Insel, S M Freeman, et al.
Seminars in Oncology|February 1, 1996
In situ use of suicide genes for cancer therapyS M Freeman, K A Whartenby, J L Freeman, et al.
Neurology|January 24, 2002
An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MSP A Calabresi, J L Wilterdink, J M Rogg, et al.
Pharmacology & Therapeutics|April 1, 1995
Gene-modified cells for the treatment of cancerK A Whartenby, G N Abraham, P A Calabresi, et al.
Journal of Neuroimmunology|June 28, 2008
Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitisM V Jones, T T Nguyen, C A Deboy, et al.
Cancer Research|November 1, 1993
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modifiedS M Freeman, C N Abboud, K A Whartenby, et al.
Leukemia|February 3, 2007
Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative diseaseB R Baldwin, L Li, K-F Tse, et al.
Pageof 2